anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This is a prospective study of pediatric patients between 0-15 years of age who were admitted in three pediatric wards: general pediatric ward aged \<5 years, general pediatric ward aged \>5 years, and pediatric intensive care unit at a tertiary-care teaching hospital. Patients who needed percutaneous blood cultures were eligible for enrollment and were classified into two groups according to antiseptic used: 10% povidone iodine in odd months and 2% chlorhexidine gluconate in 70% alcohol in even months. Blood cultures were taken primarily by ward nurses using standard technique. The blood cultures were analysed and monitored for 5 days. Isolated organisms and their antimicrobial susceptibilities were determined using standard microbiologic techniques.

Blood culture isolates were categorized into two groups including a true pathogen and a contaminant by clinical criteria combined with laboratory data. A blood culture was classified as contaminated if common skin flora such as Coagulase negative staphylococci, Corynebacterium spp., Micrococcus spp., or Bacillus spp. were isolated from one of the blood culture samples without isolation of the same organism from another potential infection site (for example, intravenous catheter), or a common skin flora was isolated in a patient with incompatible clinical features and improved without specific treatment for that organism.
In this critical review, we explore the study design, strengths and limitations of the paper: "Two-Year Outcomes of Sacral Neuromodulation Versus OnabotulinumtoxinA for Refractory Urgency Urinary Incontinence: A Randomized Trial." The paper reports 24 month follow-up data of the landmark ROSETTA trial. This multi-centre, open-labelled parallel randomised trial allocated females 1:1 to receive Sacral Neuromodulation (SNM) or OnabotulinumtoxinA(BTX) 200 units (U). The primary outcome was change in mean daily urinary urgency incontinence episodes (UUIE) over 24 months. The study did not demonstrate a difference between treatments (-3.88 vs. -3.50 episodes per day), however women treated with BTX were more satisfied; but reported higher rates of UTI. The two treatments provide comparable third-line treatment options for patients with refractory urgency urinary incontinence.
The crosslinked Marathon polyethylene liners used for the primary total hip replacements in this study were treated with 5 Mrad (50 kGy) of gamma irradiation to induce crosslinking and then heated above the melting temperature (150 degrees Celsius) to eliminate free radicals. This manufacturing process was designed to improve the polyethylene's resistance to wear through increased crosslinking and eliminate free radicals that render it susceptible to oxidative degradation. These liners were machined and terminally sterilized with gas plasma, a noncrosslinking chemical surface treatment. These liners did not have had free radicals at the time of implantation and did not incorporate antioxidants.
Atrial fibrillation (AF) is the most common cardiac arrhythmia and a major risk factor for cerebrovascular insults. Paroxysmal AF is defined as an episode of AF that terminates spontaneously or with intervention within 7 days. Patients with AF may present with palpitations, shortness of breath or sensation of light-headedness but asymptomatic episodes are also possible, especially in paroxysmal AF. The lack of continuous heart rate monitoring options makes early diagnosis of paroxysmal AF challenging. In this prospective single-center trial, the PPG wearable Corsano CardioWatch 287 sensor will be used to conduct continuous heart rate and -rhythm monitoring in patients with known paroxysmal AF. Collected data will then be analysed using a Cloud Analytics Service (Preventicus Heartbeats algorithm) and compared with data from simultaneously obtained 48-hour Holter ECG. Correctly identified AF episodes, their cumulative duration per 48 hours (AF burden) and the number of asymptomatic episodes will be assessed. In the primary analyses, the sensitivity of the PPG analysing algorithm to detect AF episodes is estimated by performing a logistic regression on detection (yes/no) with only an intercept as predictor, which is then translated to a proportion (the sensitivity). In the secondary analyses we are comparing the cumulative duration of AF episodes over 48 hours (AF burden) obtained with the PPG-sensor and Holter-ECG. In summary, the purpose of the study is to evaluate the performance and efficacy of the wearable PPG sensor and the cloud analytics service in detecting and quantifying AF episodes in patients with known history of paroxysmal AF.
According to past studies, it is often observed that changes in extracellular matrix, growth factors, and cytokines in degenerative tendons, indicating that the tendon is constantly changing. This change will in turn produce a change in the morphology of the tendon tissue in the ultrasound image. However, there have been few studies in the past literature on the correlation between constant changes in tendon-specific transcription factors and characterization on clinical ultrasound images. Therefore, the purpose of this project is to extract the effusion and damaged tendon while performing tendon repair therapy in patients with tendon tears, and to analyze the tendon-related transcription factors from histology and cytology to understand the changes in tendon homeostasis. At the same time, the interpretation of clinical ultrasound images was combined to establish the relationship between the biochemical factors of the cell tissues of chronic tendon lesions and the clinical ultrasound image. This study will help us to understand the mechanism of chronic tendinopathy.
Serious and occasionally fatal hypersensitivity (anaphylactic shock with collapse) reactions have occurred in patients receiving penicillin. The incidence of anaphylactic shock in all penicillin-treated patients is between 0.015% and 0.04%. Anaphylactic shock resulting in death has occurred in approximately 0.002% of the patients treated. Although anaphylaxis is more frequent following a parenteral administration, it has occurred in patients receiving oral penicillins.

When penicillin therapy is indicated, it should be initiated only after a comprehensive patient drug and allergy history has been obtained. If an allergic reaction occurs, the drug should be discontinued and the patient should receive supportive treatment, e.g., artificial maintenance of ventilation, pressor amines, antihistamines and corticosteroids. Individuals with a history of penicillin hypersensitivity may also experience allergic reactions when treated with a cephalosporin.
S1P receptor modulators, including PONVORY, have been associated with an increased risk of macular edema. Obtain a baseline evaluation of the fundus, including the macula, near the start of treatment with PONVORY. Perform an examination of the fundus, including the macula, periodically while on therapy and any time there is a change in vision.

In Study 1, macular edema was reported in 1.1% of PONVORY-treated patients compared to none of the patients receiving teriflunomide 14 mg.

Continuation of PONVORY therapy in patients with macular edema has not been evaluated. Macular edema over an extended period of time (i.e., 6 months) can lead to permanent visual loss. Consider discontinuing PONVORY if macular edema develops; this decision should include an assessment of the potential benefits and risks for the individual patient. The risk of recurrence after rechallenge has not been evaluated.

Macular Edema in Patients with a History of Uveitis or Diabetes Mellitus

Patients with a history of uveitis and patients with diabetes mellitus are at increased risk of macular edema during therapy with S1P receptor modulators, including PONVORY.
The invention concerns a novel method for preparing substituted anthraquinone represented by the general formula (I) in which R represents a hydrogen atom or a linear or branched alkyl group of 1 to 5 carbon atoms, a chloromethyl group, a -COCl group, a COOR' group or a -CH¿2?OR' group in which R' is a hydrogen atom or a linear or branched alkyl group of 1 to 5 carbon atoms, R¿1? represents a hydrogen atom, a hydroxyl group, a linear or branched alkyl group of 1 to 5 carbon atoms, or an acyloxy group of 1 to 5 carbon atoms, and R¿2? represents a hydrogen atom, by Diels-Alder reaction between a 1,4-naphthoquinone of general formula (II): in which R¿2? is as defined above, and X represents a hydrogen or halogen atom and an acyclic diene of formula (III): CH¿2? = CR - CH -OR¿2? in which R is as defined above, and R¿3? represents a silyl group of formula -Si(R¿4?)¿3? in which R¿4? is a linear or branched alkyl group of 1 to 5 carbon atoms, followed by an oxidising deprotecting reaction using Jones reagent for obtaining substituted anthraquinone of general formula (I). The invention is for preparing rheins useful in pharmaceutics.
INTRODUCTION: Transversus abdominis plane (TAP) blocks are commonly performed for postoperative analgesia in elective cesarean section. Ropivacaine is the most commonly used local anesthetic for TAP blocks. Currently, the concentration of ropivacaine for TAP blocks is various, and increasing number of randomized controlled trials (RCTs) have compared the effects of different concentration of ropivacaine for TAP blocks in cesarean section. This protocol of a systematic review and meta-analysis aims to identify the optimal concentration of ropivacaine for TAP blocks in elective cesarean section.
METHODS AND ANALYSIS: Databases including PubMed, Web of science, the Cochrane library, and EMBASE will be searched from their inception to May 1, 2024. RCTs that investigated the analgesia of different concentrations of ropivacaine for TAP blocks in elective cesarean section will be identified. The analgesia duration will be the primary outcome. Secondary outcomes will include the analgesics consumption over postoperative 24 hours, postoperative pain scores at rest and movement, and the incidence of adverse effects. RevMan 5.4 software will used for statistical analysis. The evidence quality of synthesized results will be evaluated by the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach.
ETHICS AND DISSEMINATION: Ethical approval is not applicable. The results of this study will be published on completion.
TRIAL REGISTRATION: PROSPERO registration number: CRD42024496907.
The experimental group will have Square Stepping Exercise training twice a week for 4 weeks. Each session will start with a 15-minute warm-up, followed by a 40-minute Square Stepping Exercise workout and ending with a 15-minute cool-down. The Square Stepping Exercise part will start with the Elementary 2 level, which has 30 different patterns. Participants will start with the first pattern at this level. If they can complete it without mistakes within 15 seconds, they'll move on to the next pattern. If not, they'll repeat the pattern until they get it right within the time limit. Each session will have four participants, with two participants working on each of the two mats, which are divided into 40 squares and measure 100cm by 250 cm.
Heparin is given to reach an ACT of 200-220 seconds. At the start of the procedure, before any heparin is given, a baseline ACT measurement is performed. 3-5 minutes before clamping of the aorta 100 IU/kg bodyweight of heparin is administrated intravenously. 5 minutes after administration of heparin, ACT measurement is performed.
Participants will be treated for symptomatic shoulder instability with the non-specific, generalized treatment intervention. For eight weeks, there will be two treatment sessions per week lasting 30-45 minutes. The NPI consists of a general approach to treating shoulder pain with passive modalities for pain modulation. These interventions are commonly practiced but have little evidence to support their use in the treatment of symptomatic shoulder instability. Although the components of the NPI will be pre-determined, the parameters and volumes of the components will be determined and documented by a study clinician over the treatment phase.
This solution is for intravenous use only after admixture or dilution. 

70% Dextrose Injection USP is designed for use with automated compounding devices for preparing intravenous nutritional admixtures or for the filling of empty sterile syringes. Dosages will be in accordance with the recommendation of the prescribing physician. 70% Dextrose Injection USP is not intended for direct infusion. Admixtures should be made by, or under the direction of, a pharmacist using strict aseptic technique under a laminar flow hood. Compounded admixtures may be stored under refrigeration for up to 24 hours. Administration of admixtures should be completed within 24 hours after removal from refrigeration.

Dosage is to be directed by a physician and is dependent upon age, weight, clinical condition of the patient and laboratory determinations. Frequent laboratory determinations and clinical evaluation are essential to monitor changes in blood glucose and electrolyte concentrations, and fluid and electrolyte balance during prolonged parenteral therapy.

Fluid Administration should be based on calculated maintenance or replacement fluid requirements for each patient.
Mutations in the SACS gene are associated with autosomal recessive spastic ataxia of Charlevoix-Saguenay disease (ARSACS) or complex clinical phenotypes of Charcot-Marie-Tooth disease (CMT). This study aimed to identify SACS mutations in a Korean CMT cohort with cerebellar ataxia and spasticity by whole exome sequencing (WES). As a result, eight pathogenic SACS mutations in four families were identified as the underlying causes of these complex phenotypes. The prevalence of CMT families with SACS mutations was determined to be 0.3%. All the patients showed sensory, motor, and gait disturbances with increased deep tendon reflexes. Lower limb magnetic resonance imaging (MRI) was performed in four patients and all had fatty replacements. Of note, they all had similar fatty infiltrations between the proximal and distal lower limb muscles, different from the neuromuscular imaging feature in most CMT patients without SACS mutations who had distal dominant fatty involvement. Therefore, these findings were considered a characteristic feature in CMT patients with SACS mutations. Although further studies with more cases are needed, our results highlight lower extremity MRI findings in CMT patients with SACS mutations and broaden the clinical spectrum. We suggest screening for SACS in recessive CMT patients with complex phenotypes of ataxia and spasticity.
PCT No. PCT/FI97/00585 Sec. 371 Date May 17, 1999 Sec. 102(e) Date May 17, 1999 PCT Filed Sep. 26, 1997 PCT Pub. No. WO98/13023 PCT Pub. Date Apr. 2, 1998The invention relates to a product containing a microcrystalline plant sterol, a method for producing the product by pulverization, and use of the product for the manufacture of edible products. The invention also relates to products manufactured using the microcrystalline plant-sterol-containing product. Preferably, the product is a spread based on a combination of a sweetening agent, a microcrystalline plant sterol and suitable berry or fruit.
<P>PROBLEM TO BE SOLVED: To provide a cosmetic having excellent characteristics of collagen, free from risk causing infection of pathogen and transmission of a pathogenic factor and having high safety.  <P>SOLUTION: The cosmetic has at least an amino acid sequence represented by the Pro-Y-Gly (wherein Y is Pro or Hyp) and is composed of a synthetic polypeptide forming a collagenous structure. The polypeptide may exhibit a positive Cotton effect in 220-230 nm wavelength and exhibit a negative Cotton effect in 195-205 nm in a circular dichroism spectrum. At least a part of the polypeptide may form a triple helical structure. The cosmetic may be a powdery cosmetic, a solid or semi-solid cosmetic or a liquid cosmetic.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
Scalp nerve block with 10-15 ml of 0.9% sodium chloride(NaCl), or normal saline (NSS) includes 4-6 nerves which give sensory supply to related location (sham block). Intravenous fentanyl is used for intraoperative analgesia in both groups with continuous infusion (1 mcg/kg/hr until opening of dura and then 0.5 mcg/kg/hr until finishing of dural closure) and increment doses (0.5 mcg/kg) also given.
PURPOSE: A novel anticancer aid compound and a composition containing the same for anticancer are provided to be used as a chemosensitizer which reduces anticancer drug resistance. CONSTITUTION: A novel anti cancer aid compound is denoted by chemical formula I. The compound of chemical formula I is 8,10-bis(tiirane-2-ylmethoxy)-7H-benzo[c]xanthene-7-one or 1,3-bis(tiirane-2-ylmethoxy)-12H-benzo[b]xanthene-12-one. A compound of chemical formula I-1 is prepared by reacting epichlorohydrin or epithiochlorohydrin with a compound of chemical formula II under the presence of base. The base is K_2CO_3, CS_2CO_3, NaOH or NaH. An aid pharmaceutical composition for anticancer contains the compound of chemical formula I and pharmaceutically acceptable salt thereof.
BACKGROUND: Magnesium ion metabolism disorder is pervasive in the chronic kidney disease population, which is affected by many factors. Magnesium ion plays an important role in maintaining vascular functional integrity.. The Magnesium Depletion Score (MDS), serving as a novel metric for the assessment of magnesium deficiency, has not been thoroughly investigated for its association with stroke in patients with chronic kidney disease (CKD). Therefore, this study aims to explore the relationship between the MDS index and stroke in CKD patients.
METHODS: We conducted a cross-sectional population-based study using data from the National Health and Nutrition Examination Survey 2009-2016 to explore the impact of MDS on the stroke outcome of CKD patients. The primary outcome was the risk of stroke in CKD patients. Sample-weighted multivariate logistic regression was used in our analysis.
RESULTS: In this study of 3536 CKD patients from the database, we found an 8.6 % prevalence of stroke with higher stroke risk in older individuals and males. Lower dietary magnesium intake and higher MDS scores were significantly associated with stroke risk. Multivariate logistic regression analysis revealed a dose-dependent relationship between MDS scores and stroke likelihood, independent of demographic and clinical factors. Subgroup analysis confirmed these findings, particularly in those with hypertension, diabetes, and obesity, without significant interactions (all p > 0.05).
CONCLUSION: Magnesium depletion is independently associated with a heightened stroke risk in chronic kidney disease patients.
After a single 4 mg oral dose of 14C-labelled cyproheptadine HCl in normal subjects, given as tablets, 2 to 20% of the radioactivity was excreted in the stools. Only about 34% of the stool radioactivity was unchanged drug, corresponding to less than 5.7% of the dose. At least 40% of the administered radioactivity was excreted in the urine. No detectable amounts of unchanged drug were present in the urine of patients on chronic 12 to 20 mg daily doses. The principle metabolite found in human urine has been identified as a quaternary ammonium glucuronide conjugate of cyproheptadine. Elimination is diminished in renal insufficiency.
OBJECTIVE: Post-lumbar fusion surgery often restricts daily activities due to lumbar stiffness. The validity and reliability of the lumbar stiffness disability index (LSDI) in Türkiye, which measures the impact of lumbar stiffness on functional abilities, have not yet been confirmed. This study aims to test the validity and reliability of the Turkish version of LSDI (Tr-LSDI).
METHODS: Sixty-six patients who underwent lumbar fusion surgery were included in this methodological study. The Tr-LSDI was developed using a forward-backward translation. Using the Davis technique and expert feedback, we confirmed the content validity (CV) of the Tr-LSDI. The construct validity of the Tr-LSDI was assessed with exploratory factor analysis (EFA) and convergent validity. Convergent validity was examined by correlation analysis between Tr-LSDI, the Oswestry disability index (ODI) scores, and the number of fusion levels. Internal consistency was determined using Cronbach's alpha coefficients, and test-retest reliability was assessed with the intraclass correlation coefficient (ICC).
RESULTS: Expert evaluation yielded CV indexes > 0.8 for all items. Exploratory factor analysis revealed a one-factor structure for Tr-LSDI, comprising 10 items that accounted for 63.7% of the variance. Factor loadings spanned from 0.371 to 0.926. Notably, the Tr-LSDI score correlated with fusion levels (r=0.386, P=.001) and demonstrated a robust correlation with ODI (r=0.899, P < .001), affirming its convergent validity. The Tr-LSDI displayed excellent internal consistency with a Cronbach's alpha coefficient of 0.934. The ICC was 0.980.
CONCLUSION: The Tr-LSDI is a validated, reliable tool for measuring lumbar stiffness in Türkiye. Its consistency, validity, and alignment with the original LSDI make it suitable for clinical and research use.
LEVEL OF EVIDENCE: Level II, Diagnostic Study.
Those subjects in the liposomal bupivacaine arm will have 30mL dilutional volume injected. Ten mL will be injected into the perineum in the posterior vaginal area and 20 mL will be injected the port site wounds in the abdomen (5 sites, 4 ml per incision).
FIELD: organic chemistry, medicine, pharmacy. SUBSTANCE: invention relates to derivatives of 1,2,4-thidiazole substituted by position 5 of the general formula (I)   where X means N atom; R 1  means C 1-6 -alkyl; R 2  means hydrogen atom; each of R 3 , R 4 , R 5  is taken independently among hydrogen atom, trifluoromethyl group;   means Ar 2 , Ar 2 CH 2 - or Het 2  where Ar 2  means phenyl; Het 2  means monocyclic heterocycle taken among thiadiazolyl, pyridinyl, pyrimidinyl or pyrazinyl, their N-oxide forms, pharmaceutically acceptable acid-additive salts and stereochemical isomeric forms. Invention describes also methods of synthesis of these compounds, intermediate substances used in synthesis and method of synthesis of intermediate substance. Compounds act as inhibitors of angiogenesis and therefore they can be used in treatment the following diseases: diabetic retinopathy, angiofibroma, psoriasis, osteoarthrosis and others. EFFECT: improved methods of synthesis, valuable medicinal properties of compounds. 10 cl, 3 tbl, 6 ex
The present invention relates to a poly(allylamine) polymer and, more generally, a hydrocarbon amine polymer. Preferably, these polymers are crosslinked. The present invention also relates to methods of forming these polymers and methods for their use. Further, the present invention relates to alkylating agents that can be employed to form the polymers and to methods for forming the alkylating agents. Generally, the polymer sequestrant includes a substituent bound to an amine of the polymer. The substituent includes a quaternary amine-containing moiety having one, two or three terminal hydrophobic substituents. A method of preparing quaternary amine-containing alkylating agents includes reacting an unsymmetrical dihalide with a tertiary amine having at least one hydrophobic substituent. A method for binding bile salts of bile acids in a mammal includes orally administering to the mammal a therapeutically-effective amount of the polymer sequestrant.
Injection of a single dose of 185MBq ( range 150-220MBq) of \[131\]I-IAZA prior to whole body imaging acquisition at 0-1 hrs,1-3 hrs , 4-8 hrs,19-36 hrs,41-72 hrs and 6-8 days post-injection. SPECT CT of target lesion(s) will be acquired at 19-36 hrs post injection.